Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Cash Flows (Unaudited)

v3.19.2
Condensed Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended 21 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Sep. 30, 2018
Jun. 30, 2019
Operating Activities            
Net loss $ (114,030) $ 103,999 $ (525,405) $ (19,949)    
Adjustments to reconcile net loss to net cash used in operating activities:            
Interest earned on cash and marketable securities held in Trust Account     (2,105,087) (1,144,095)    
Interest receivable on cash and marketable securities held in Trust Account     (155,566)      
Change in operating assets and liabilities:            
Receivable from related party     (717) (8,570)    
Prepaid expenses     78,457 (182,318)    
Accounts payable     1,210,880 105,837    
Payable to related party     44,119      
Accrued liabilities     (141,918)      
Other current liabilities     (18,847) 195,156    
Net cash used in operating activities     (1,614,084) (1,053,939)    
Investing Activities            
Investment of cash in Trust Account, net     (1,677,500) (143,750,000)    
Interest income used to pay taxes     949,462 183,677    
Cash withdrawn from Trust Account     70,180,359   $ 379,123 $ 1,328,585
Net cash provided by (used in) investing activities     69,452,321 (143,566,323)    
Financing Activities            
Proceeds from sale of Units, net of underwriting discounts paid       141,162,440    
Proceeds from sale of Private Placement Shares       4,982,560    
Proceeds from the sale of Founder Shares       25,000    
Promissory notes from related parties       50,536    
Repayment of promissory notes from related parties       (50,536)    
Payment of deferred offering costs       (664,499)    
Redemption of common stock     (70,180,359)      
Promissory notes issued in conjunction with extension     2,074,099      
Net cash provided by (used in) financing activities     (68,106,260) 145,505,501    
Net change in cash and cash equivalents     (268,023) 885,239    
Cash and cash equivalents, beginning of period     597,268      
Cash and cash equivalents, end of period $ 329,245 $ 885,239 329,245 885,239 $ 597,268 $ 329,245
Supplemental disclosure of noncash investing activities            
Change in value of common stock subject to possible redemption     $ 525,405 $ 104,000